Skip to main content

Tweets

Genetic Risks and Severe Cutaneous Reactions to Allopurinol A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 1 day ago
Swedish Birth Registry study of adverse preg outcomes (APOs) after SSc Dx [n=941] or w/in 3 yrs [39] or > 3yrs pre-Dx [839]. SSc women have incr APOs post-Dx, including preeclampsia (RR 3.8), preterm (3.3), C-section (2.5); but also incr APO risk w/in 3 yrs of Dx

Dr. John Cush @RheumNow ( View Tweet )

2 weeks 1 day ago
NHANES study of 4,622 adults, including 296 w/ RA, shows volatile organic compounds (VOCs) & metabolites (mVOCs) exposures increases the risk of #RA (OR: 1.23 - 1.37), especially in females. https://t.co/pBNLTRkyLn https://t.co/L6nVbYlBhD
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 1 day ago
#ACR25 PsA Topic Panel A focused conversation on the latest in psoriatic arthritis care - from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now. https://t.co/PP0fkweXsZ
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 1 day ago
New Approaches to Therapy in PsA Dr. Arthur Kavanaugh offers an overview of new approaches to therapy in psoriatic arthritis, at #ACR25. https://t.co/9vHgQ6S2JD https://t.co/5mvX1rOrIP
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 1 day ago
Why I love the late breaking abstracts https://t.co/jCSfNOoFeT https://t.co/uZWSm9SQAI
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 2 days ago
Tuesday Nite Rheumatology (on 11.11.25) https://t.co/xk8NOwLN7z

Dr. John Cush @RheumNow ( View Tweet )

2 weeks 2 days ago
The Interview (11.7.2025) I've conducted thousands of interviews, mainly for medical school admissions and medical or research jobs. They're all similar, with me seeking the "right one" and interviewees feeling apprehensive, uncertain, and hopeful. My extensive experience has https://t.co/KZzfEKx4qm
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 2 days ago
Late-Breaking Trials in axSpA and PsA https://t.co/EWeF0nkb1h https://t.co/HgY0be0PDX
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 2 days ago
Diagnostic Delays in PsA: A Radiographic Perspective Dr. Brian Jaros reports on abstract 1713 (Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients), presented at #ACR25. https://t.co/iLllm7DcCF
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 2 days ago
S.Korean study of 481 pts w/ myositis (IIM) - 12.9% (n = 62) had myositis-assoc. cancer. CA risk factos= older age, male, current smoking, dermatomyositis, TIF1γ; but lower risk w/ anti-synthetase synd, overlap myositis, arthritis, & ILD. SCRIM score had AUROC = 0.852 https://t.co/MdU1fRWWgS
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 2 days ago
Genentech announced positive results from the phase III DBRPCT ALLEGORY trial showin safety & efficacy of obinutuzumab in ~300 SLE pts on SOC. Results have yet to be presented publicly. https://t.co/4hoT9dBtPq

Dr. John Cush @RheumNow ( View Tweet )

2 weeks 2 days ago
×